EP
CSTL icon

Essential Partners’s Castle Biosciences CSTL Stock Holding History

Essential Partners’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6.79K Buy
191
+1
+0.5% +$30 ﹤0.01% 1368
2026
Q2 		$4.53K Buy
190
+61
+47% +$1.36K ﹤0.01% 1592
2026
Q1 		$3.17K Sell
129
-5
-4% -$164 ﹤0.01% 1797
2025
Q4 		$5.21K Buy
134
+11
+9% +$355 ﹤0.01% 1409
2025
Q3 		$2.8K Buy
+123
New +$2.5K ﹤0.01% 1669

Other funds holding CSTL

Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
FBT
First Bank & Trust Brookings, South Dakota $687M AUM 18.35% 1-Year Est. Return
GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
Oak Harvest Investment Services
Oak Harvest Investment Services Houston, Texas $1.07B AUM 32.83% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Newbridge Financial Services Group
Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Essential Partners's CSTL Position: Q3 2026 in Review

Essential Partners increased its Castle Biosciences (CSTL) stake by 0.53% in Q3 2026, buying an estimated $30 and bringing the position to 191 shares worth $6.79K. The position accounts for ﹤0.01% of the portfolio, ranked #1368.

Essential Partners first reported a position in CSTL in Q3 2025 and has held it in 5 quarters since. 14 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.

  • Essential Partners held 191 shares of Castle Biosciences worth $6.79K as of Q3 2026.
  • Essential Partners bought 1 Castle Biosciences share in Q3 2026, an estimated $30.
  • Castle Biosciences made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #1368 holding.
  • Essential Partners first reported a position in Castle Biosciences in Q3 2025 and has held it in 5 quarters since.
  • 14 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.